AMWILL HEALTHCARE is amongst India's fastest growing Dermatology companies with a keen focus on Dermatology, Trichology & Cosmetology. They focuses on modernity; the development of its products is based on "High-Tech" advanced active cosmetology and dermatology, based on natural ingredients, allopathic actives and special technique, which offer effective and visible results.
Amwill Healthcare, an Book Built Issue amounting to ₹ 59.97 Crores, consisting an fresh issue of 44.03 Lakh Shares worth 48.87 Crores and an Offer for Sale of 10.00 Lakh Shares totalling to 11.1 Crores. The subscription period for the Amwill Healthcare IPO opens on February 5, 2025, and closes on February 7, 2025. The allotment is expected to be finalized on or about Monday, February 10, 2025, and the shares will be listed on the BSE SME with a tentative listing date set on or about Wednesday, February 12, 2025.
The Share price of Amwill Healthcare IPO is set at ₹ 105 to ₹ 111 per equity share. The Market Capitalisation of the Amwill Healthcare Limited at IPO price of ₹ 111 per equity share will be ₹ 222.04 Crores. The lot size of the IPO is 1,200 shares. Retail investors are required to invest a minimum of ₹ 1,33,200, while the minimum investment for High-Net-Worth Individuals (HNIs) is 2 lots (2,400 shares), amounting to ₹ 2,66,400.
Unistone Capital Private Limited is the book running lead manager of the Amwill Healthcare IPO, while Bigshare Services Private Limited is the registrar for the issue. Globalworth Securities Limited is the Market Maker for Amwill Healthcare IPO.
Amwill Healthcare Limited IPO GMP Today
The Grey Market Premium of Amwill Healthcare Limited IPO is expected to be ₹ 0 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Amwill Healthcare Limited Day Wise IPO GMP Trend
Date |
IPO Price |
Expected Listing Price |
GMP |
Last Updated |
1 February 2025 | ₹ 111 | ₹ 111 | ₹ 0 (0%) | 01:00 PM; 1 Feb 2025 |
Amwill Healthcare Limited IPO Live Subscription Status Today: Real-Time Update
Amwill Healthcare IPO will be open for its Subscription on 5 February, 2025.
Amwill Healthcare Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online
Amwill Healthcare IPO allotment date is 10 February, 2025, Monday. Amwill Healthcare IPO Allotment will be out on 10 February, 2025 and will be live on Registrar Website from the allotment date. Check Amwill Healthcare IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Amwill Healthcare Limited IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID.
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Amwill Healthcare Limited IPO
Amwill Healthcare proposes to utilise the Net Proceeds towards the following objects:
1. ₹ 2,500.00 Lakhs is required for Funding of working capital requirements of the Company
2. ₹ 500.00 Lakhs is required for Marketing and brand building activities
3. General corporate purposes
Refer to Amwill Healthcare Limited RHP for more details about the Company.
Check latest IPO Review & analysis, Live IPO GMP today, Live IPO Subscription Status Today, Share Price, Financial Information and other details before applying in the IPO.
The Upcoming IPOs in this week and coming weeks are Chamunda Electricals, Ken Enterprises, Amwill Healthcare, Readymix Construction, Eleganz Interiors.
No Current active IPO.
The Closed IPOs are Malpani Pipes And Fittings and Dr. Agarwal's Health Care.
The Recently Listed IPOs which is available for trading in stock Market are Sat Kartar Shopping, Fabtech Technologies, Unimech Aerospace, Senores Pharmaceuticals, Mamata Machinery, DAM Capital, Identical Brain Studios, NACDAC Infrastructure, Hamps Bio, Yash Highvoltage, Jungle Camps, Toss The Coin, Dhanlaxmi Corp, Emerald Tyre Manufacturers, Nisus Finance, Ganesh Infraworld, Agarwal Toughened, Apex Ecotech, Rajputana Biodiesel, Rajesh Power Services, C2C Advanced System, Enviro Infra Engineers, Waaree Energies Limited IPO, Diffusion Engineers Limited IPO, KRN Heat Exchanger Limited IPO, P N Gadgil Jewellers Limited IPO, Bajaj Housing Finance Limited IPO, Gala Precision Engineering Limited IPO, Premier Energies Limited IPO, Orient Technologies Limited IPO, Interarch Building Products Limited IPO, Unicommerce eSolutions Limited IPO and many more.
Amwill Healthcare IPO Details |
|||||||||||
IPO Date | February 05, 2025 to February 07, 2025 | ||||||||||
Listing Date | February 12, 2025 | ||||||||||
Face Value | ₹10 | ||||||||||
Price | ₹ 105 to ₹ 111 per share | ||||||||||
Lot Size | 1,200 Equity Shares | ||||||||||
Total Issue Size | 54,03,600 Equity Shares (aggregating Up to ₹ 59.97 Cr) | ||||||||||
Fresh Issue | 44,03,600 Equity Shares (aggregating Up to ₹ 48.87 Cr) | ||||||||||
Offer for Sale | 10,00,000 Equity Shares (aggregating Up to ₹ 11.1 Cr) | ||||||||||
Issue Type | Book Built Issue | ||||||||||
Listing At | BSE SME | ||||||||||
Share holding pre issue | 1,56,00,000 | ||||||||||
Share holding post issue | 2,00,03,600 |
Amwill Healthcare IPO Lot Size |
|||||||||||
Application | Lots | Shares | Amount | ||||||||
Retail (Min) | 1 | 1,200 | ₹1,33,200 | ||||||||
Retail (Max) | 1 | 1,200 | ₹1,33,200 | ||||||||
S-HNI (Min) | 2 | 2,400 | ₹2,66,400 | ||||||||
S-HNI (Max) | 7 | 8,400 | ₹9,32,400 | ||||||||
B-HNI (Min) | 8 | 9,600 | ₹10,65,600 |
Amwill Healthcare IPO Timeline (Tentative Schedule) |
|||||||||||
IPO Open Date | Wednesday, February 5, 2025 | ||||||||||
IPO Close Date | Friday, February 7, 2025 | ||||||||||
Basis of Allotment | Monday, February 10, 2025 | ||||||||||
Initiation of Refunds | Tuesday, February 11, 2025 | ||||||||||
Credit of Shares to Demat | Tuesday, February 11, 2025 | ||||||||||
Listing Date | Wednesday, February 12, 2025 | ||||||||||
Cut-off time for UPI mandate confirmation | 5 PM on February 7, 2025 |
Amwill Healthcare IPO Reservation |
|||||||||||
Investor Category | Shares Offered | Reservation % | |||||||||
QIB Portion | 10,26,000 | Not More than 20% of the Issue | |||||||||
Non-Institutional Investor Portion | 20,53,200 | Not Less than 40% of the Issue | |||||||||
Retail Shares Offered | 20,53,200 | Not Less than 40% of the Issue | |||||||||
Market Maker Portion | 2,71,200 | 5.02% of the Issue |
Amwill Healthcare IPO Promoter Holding |
|||||||||||
Share Holding Pre Issue | 97.00% | ||||||||||
Share Holding Post Issue | 70.65% |
Amwill Healthcare IPO Subscription Status |
|||||||||||
Investor Category | Shares Offered | Shares Bid For | No oF Times Subscribed | ||||||||
Qualified Institutional Buyers (QIB) | 10,26,000 | - | 0.00 | ||||||||
Non Institutional Investors(NIIS) | 23,24,400 | - | 0.00 | ||||||||
Retail Individual Investors (RIIs) | 20,53,200 | - | 0.00 | ||||||||
Total | 54,03,600 | - | 0.00 |
Business Overview
Amwill Healthcare specializes in derma-cosmetic development, collaborating with contract manufacturers, distributors, and third-party agencies. The company focuses on problem-solving dermatological, cosmeceutical, and aesthetic products, outsourcing manufacturing, prototype development, and distribution for efficiency.
Operations are concentrated in Karnataka, Andhra Pradesh, and Telangana, with plans to expand into West Bengal and Odisha. The product portfolio includes:
Since inception, seven products have been developed, including XL Hydra Cream, XL Aqua Moisturising Lotion, and Ultra Kromaglo Effervescent Tablets, while three products were discontinued due to low market response. Managing Director Anand Gandhi leads product development, focusing on solutions for acne, fungal infections, anti-aging, hyperpigmentation, and vitiligo.
Storage and distribution are handled by Amderma Healthcare LLP under a Carrying and Forwarding Agreement (CF Agreement) effective January 1, 2024. All revenue is derived from Amderma, which manages orders from wholesalers, doctors, hospitals, and nursing homes.
Promoter and Managing Director Tarun Gandhi has built a structured sales hierarchy across key states. Marketing strategies include direct engagement with doctors, participation in scientific exhibitions, and advertising in medical journals. As on September 30, 2024, the Company's marketing team consists of 59 employees. The Banker to the Company is Kotak Mahindra Bank Limited
Industry Analysis
INDIA COSMETIC MARKET
India’s $14 billion beauty and personal care industry is on a roll thanks to online sales of beauty products, premiumisation, and an inclination towards organic and ethical brands. According to a report by research firm Euromonitor International, last year, with the presence of online retailers like Nykaa.com and Amazon.com, the beauty and personal care products category crossed $400 million in internet sales up from $100 million in 2014.
The high penetration of smartphones and easy access to the internet that exists on the fingertips of 560 million Indians (TRAI data for September 2018) today is driving the continued rise of the beauty and personal care industry in the country. With the number of internet users in the country expected to cross Europe’s population by 2025, it is no surprise that the beauty and personal care industry is enjoying rapid growth, accelerated by an increase in internet retailing.
According to the Euromonitor International report, since technology has been driving growth in most industries, including beauty and personal care, companies are rethinking the relevance of physical stores and revamping them. Businesses are developing ways to drive engagement as well as TO transform the in-store experience for consumers. "Physical stores continue to remain relevant in India with retailers focusing on enhancing the shopping experience by housing beauty studios with personalized beauty advisors who help consumers understand latest and trending make-up looks and regimes," the report said.
Internet connectivity has also caused a shift in consumers’ consumer’s traditional power structures, wherein recommendations from families and friends and independent consumer reviews have greater credence over mass marketing channels like celebrity endorsements, in-store advertising etc, according to the Euromonitor International Lifestyles Survey 2019.
Premiumisation, which essentially refers to the ability and willingness to spend on exclusive, superior quality goods, is of late becoming more popular with the Indian consumer. Indians are no longer afraid to put up extra bucks to purchase premium products. Such products come largely in partnership with a luxury or premium brand, like the lipstick launched by L’Oreal in collaboration with Indian couture designer Sabyasachi, or products personally formulated or customised in accordance to the specific needs of customers. Companies like Freshistry and Emcee Beauties produce customised products taking the needs of their customers into consideration, Euromonitor said.
Premiumisation has especially driven the demand for beauty and personal care products. The Euromonitor International study shows that in 2018, $774 million worth of premium beauty and personal care products were sold in India, with 63% share enjoyed by premium fragrances and hair care products. According to the study, with increasing disposable incomes, the per capita expenditure on premium personal care and beauty products is expected to show a CAGR of 15% from 2018 to 2023.
Meaningful consumerism has also been shaping the beauty and personal care industry as customer focus shifts towards conscious consumption and ethical living.
With India having 22 of the world’s 30 most polluted cities (2018 air quality data by Greenpeace), consumers are becoming increasingly aware of environmental degradation and switching to eco-friendly, organic AND , natural products. The Euromonitor International Lifestyles Survey (2019) shows that respondents have the greatest understanding of, and trust in(,) environmentally conscious and eco-friendly products (67%), followed by natural products (66%), and organic products (65%). Brands like SoulTree offer certified natural beauty and personal care products, while Ruby’s Organic offers organically made cosmetics. Many other companies are looking into creating recyclable products, or products that are free of any artificial ingredients.
Over the last decade, India has seen consistent growth in the personal care and cosmetics market with increasing shelf space in boutiques and retail stores across the country. Many multinational brands have entered the Indian market, primarily aided by dedicated support structure and their respective pricing strategies. The Indian cosmetics industry is majorly categorised into skin care, hair care, oral care, fragrances, and colour cosmetics segments. The overall market share is expected to grow to US$ 20 billion by 2025 with a Compound Annual Growth Rate (CAGR) of 25%. On the other hand, the global cosmetics industry is growing at 4.3% CAGR and will reach US$ 450 billion by 2025.
By 2025, along with this growth, India will constitute 5% of the total cosmetics market and reach the top five global markets in terms of revenue. Additionally, the market will continue to rise strongly due to consumers' growing choice of speciality cosmetic products such as organic, herbal, and ayurvedic items. Colour cosmetics, perfumes, specialised skin care, hair care, and makeup cosmetics are the main industries predicted to increase. The market competition for domestic brands is increasing due to a growing number of international companies entering the Indian personal care and cosmetics market. However, the bigger players in the industry like Dabur and Marico continue to dominate the market due to the availability of ayurvedic and herbal cosmetic products in their respective product portfolios. Due to the widespread belief among customers that foreign brands are of higher quality; international cosmetics brands have had a significant impact on the Indian market. Aspirational customers have been drawn to these brands, which have accelerated the growth of the Indian market. Indian customers are switching from basic functional products to more sophisticated and specialised cosmetic products, which is driving up demand for high-end goods in India.
Many international brands like Revlon, Avon, Burberry, Calvin Klein, Cartier, Christian Dior, Estee Lauder, Elizabeth Arden, Lancome, Chambor, Coty, L'Oreal, Oriflame, Yardley, Wella, Schwarzkopf, Escada, Nina, Ricci, Rochas, Yves St. Laurent, Tommy Hilfiger, Max factor, Max Mara, Shiseido, Body Shop, Maybelline New York, MAC and many more like these have been present in India for quite some time now.
The Indian beauty market continues to be one of the fastest-growing ones in the entire world. India is one of the most attractive countries for multinational corporations aiming to increase their market share, with a population of over a billion people and rising disposable income.
Indian businesses looking to access this market still face difficulties, notwithstanding this development. For instance, the Indian beauty sector has undergone a substantial amount of consolidation in recent years as huge global businesses have tried to tap into the lucrative market. This has led to a more competitive environment where many smaller competitors struggle to stay competitive and maintain business growth.
The cosmetic industry in India has emerged as a luminous gem in the country's economic landscape. The Indian cosmetic industry has embarked on a stellar trajectory, defying conventional norms and products with a stable market value of over US$ 3 billion. These items show the highest level of resistance to the pandemic epidemic, the financial hardships brought on by domestic limitations, and months of a blockade. The categories most impacted by social interaction and living away from home were makeup products that block sunlight, as well as fragrances. This growth can be attributed to several key factors. Chief among them is the changing consumer landscape in India. As incomes rise and urbanization spreads its wings. Indian consumers are increasingly discerning and quality-conscious. The demand for cosmetics and personal care products is on the rise, and this trend is set to continue in the coming years. Both established firms and newbies have a wealth of potential in the Indian cosmetics market. The growth of product portfolios is one of the most promising options. A growing demand for niche and specialised items is being driven by increasingly sophisticated consumers. Companies have a fantastic potential to diversify and meet certain customer needs because of this. Additionally, India's vibrant cultural legacy is inextricably related to the country’s beauty and wellness sector, of which cosmetics are a crucial component. The ancient Indian system of healing and wellness known as Ayurveda is increasingly being used in cosmetics. This blending of age-old knowledge and cutting-edge science not only opens new avenues for innovation but also appeals to consumers who are concerned about their health all around the world. The digital revolution has also paved the way for unprecedented opportunities. E-commerce platforms have democratized access to cosmetics, reaching customers in every nook and cranny of the country. This expansive reach allows companies, big and small, to tap into previously untapped markets.
Business Strengths
1. Scalable Asset-Light Business Model
Amwill Healthcare operates on an asset-light and cost-efficient business model by outsourcing key functions such as manufacturing, prototype development, testing, and distribution. This approach enables a focus on product formulation, development, marketing, and sales while maintaining cost flexibility and operational scalability. Manufacturing partnerships ensure high-quality production without heavy capital investment, and Amderma Healthcare LLP manages storage and distribution, reducing direct operational costs.
2. Diverse Product Portfolio with Strong Formulation Capabilities
The company develops advanced generic formulations and targeted dermatological solutions, enhancing product efficacy and market relevance. The leadership team, with over two decades of experience in the pharmaceutical sector, collaborates with dermatologists to identify market needs and drive innovative product development.
3. Quality-Driven Product Development through Strategic Partnerships
Stringent quality control measures are implemented by working with contract manufacturers and prototype developers. Each formulation undergoes thorough testing to ensure the desired composition, texture, and effectiveness. Regulatory compliance, manufacturing best practices, and formal agreements with manufacturers guarantee product consistency and accountability. Continuous feedback from distributors, managers, and medical professionals drives ongoing product improvements.
4. Experienced Leadership with Strong Execution Capabilities
Led by Tarun Gandhi and Anand Gandhi, the management team brings extensive expertise in business development, finance, marketing, sales, and product innovation. Their strategic insights have facilitated business expansion, dermatologist collaborations, and efficient project execution. The experienced technical and operational team plays a crucial role in scaling operations and navigating industry dynamics, ensuring sustained growth and market presence
Business Strategies
1. Expanding Product Portfolio and Delivery Systems for Growth
Aiming to enhance revenue growth through a diverse product mix, Amwill Healthcare focuses on developing innovative derma-cosmetic solutions. Investments in product development and contract manufacturing will drive the launch of new formulations and advanced delivery systems, ensuring a competitive edge and first-mover advantages in the market.
2. Market Diversification and Expansion into Untapped Regions
Currently operating in Karnataka, Andhra Pradesh, and Telangana, the company is expanding into West Bengal and Odisha, with regional sales teams already deployed. Growth strategies include sub-geographic penetration, market diversification, and international expansion, leveraging product innovation to capture untapped opportunities.
3. Strengthening Marketing and Customer Outreach
A robust marketing network is being reinforced to increase customer reach and segment diversification. The company prioritizes customized product applications, sustainable practices, and high-quality standards to enhance customer loyalty. Efforts include expanding the marketing team with experienced professionals and ensuring compliance with customer specifications and international standards as a key marketing strategy
Business Risk Factors and Concerns
1. Dependence on Product Innovation for Commercial Success
The company’s success relies on its ability to develop innovative derma-cosmetic products. Since incorporation, only a limited number of products have been developed, with some discontinued due to low market response. Failure to introduce new and effective formulations may lead to a stagnant and conventional product portfolio, impacting revenue and profitability.
2. Geographical Concentration Risk
Operations are primarily concentrated in Karnataka, Andhra Pradesh, and Telangana, making the business highly dependent on the economic, regulatory, and social conditions in these regions. Any political disruptions, natural calamities, or regulatory changes in these states may adversely impact revenue, cash flow, and business operations.
3. Risk of Patent Infringement
The industry is prone to extensive patent litigation, including lawsuits from competitors that could result in injunctions, financial penalties, or forced royalty payments. Unintentional patent infringement could restrict product sales and negatively affect the company's financial health and market presence.
4. Dependence on Key Products for Revenue
A significant portion of revenue is derived from select products, making the company vulnerable to declining sales volume or pricing. Factors such as raw material shortages, manufacturing disruptions, changing consumer demand, or regulatory withdrawals could impact financial stability. Previous product withdrawals due to low customer response and profit margins highlight this risk, which could negatively affect future business performance.
Amwill Healthcare faces risks related to limited product innovation, regional market dependency, potential patent litigation, and revenue concentration on key products. The company's long-term success depends on its ability to expand its product portfolio, diversify geographically, and navigate regulatory challenges while maintaining financial stability.
Period Ended | Sep 30, 2024 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
---|---|---|---|---|
Reserve of Surplus | 807.52 | 1,710.86 | 457.23 | 145.79 |
Total Assets | 2,888.66 | 1,898.01 | 1,239.43 | 658.75 |
Total Borrowings | 26.40 | 28.82 | 30.35 | 26.61 |
Fixed Assets | 109.28 | 55.35 | 48.95 | 38.67 |
Cash | 1,318.19 | 327.78 | 685.36 | 240.8 |
Net Borrowing | -1,291.79 | -298.96 | -655.01 | -214.19 |
Revenue | 2,324.71 | 4,428.41 | 3,028.25 | 2,761.54 |
EBITDA | 893.04 | 1,700.27 | 441.19 | 366.22 |
PAT | 651.66 | 1,253.63 | 311.44 | 257.37 |
EPS | 4.18 | 8.04 | 2 | 1.65 |
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2024 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2024 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2024 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on Cap Price Post Offer, given in FINANCIAL EXPRESS.
Key Performance Indicator |
|||||||||||
KPI | Values | ||||||||||
EPS Pre IPO (Rs.) | ₹8.04 | ||||||||||
EPS Post IPO (Rs.) | ₹6.27 | ||||||||||
P/E Pre IPO | 13.81 | ||||||||||
P/E Post IPO | 17.71 | ||||||||||
ROE | 73.06% | ||||||||||
ROCE | 94.16% | ||||||||||
P/BV | 3.06 | ||||||||||
Debt/Equity | 0.01 | ||||||||||
RoNW | 73.06% |
Amwill Healthcare Limited IPO Peer Comparison |
|||||||||||
Company Name | EPS | ROCE | ROE | P/E (x) | P/Bv | Debt/Equity | RoNW (%) | ||||
Amwill Healthcare Limited | ₹ 6.27 | 94.16 % | 73.06 % | 17.71 | 3.06 | 0.01 | 73.06 % | ||||
Vaishali Pharma Limited | ₹ 0.10 | 5.72 % | 1.73 % | 170 | 2.77 | 0.19 | 1.73 % | ||||
Trident Lifeline Limited | ₹ 10.3 | 19.1 % | 14.3 % | 25.2 | 5.07 | 0.15 | 14.3 % |
AMWILL HEALTH CARE LIMITED
No. 157, 1st Floor, 2nd Main, 3rd Cross Chamrajpet, Bangalore – 560 018, Karnataka, India.
Contact Person : Sapna Parmar
Telephone : +91 804 302 6281
Email ID : amwill@amwillhealthcare.com
Website : https://www.amwillhealthcare.com/
Registrar : Bigshare Services Private Limited
Telephone : +91 226 263 8200
Contact Person : Vinayak Morbale
Website : https://www.bigshareonline.com/
Lead Manager : Unistone Capital Private Limited
Telephone : +91 982 005 7533
Contact Person : Brijesh Parekh
Email ID : mb@unistonecapital.com
Website : https://unistonecapital.com/
AMWILL HEALTHCARE is amongst India's fastest growing Dermatology companies with a keen focus on Dermatology, Trichology & Cosmetology. They focuses on modernity; the development of its products is based on "High-Tech" advanced active cosmetology and dermatology, based on natural ingredients, allopathic actives and special technique, which offer effective and visible results.
The Company is led by a group of individuals, having a strong background and extensive experience in the dermatological and pharmaceutical industry. The Promoters and Managing Directors, Tarun Gandhi and Anand Gandhi have been associated with them since the inception. They are the founding members and are actively involved in the strategic decision making for the Company, pertaining to corporate and administrative affairs, financial operations, expansion activities, business development and management of overall business. The Promoter, Tarun Gandhi heads the business development and finance and accounts divisions of the Company and the Promoter, Anand Gandhi, heads the marketing and sales, product development, dermatologist relations divisions of the Company.
The Revenues from operations for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 2,324.71 Lakh, ₹ 4,428.41 Lakh, ₹ 3,028.25 Lakh and ₹ 2,761.54 Lakh respectively. The EBITDA for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 893.04 Lakh, ₹ 1,700.27 Lakh, ₹ 441.19 Lakh, and ₹ 366.22 Lakh, respectively. The Profit after Tax for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 651.66 Lakh, ₹ 1,253.63 Lakh, ₹ 311.44 Lakh, and ₹ 257.37 Lakh respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹ 8.04 and post-issue EPS of ₹ 6.27 for FY24. The pre-issue P/E ratio is 13.81x, while the post-issue P/E ratio is 17.71x against the Industry P/E ratio is 36x. The company's ROCE for FY24 is 94.16%, ROE for FY24 is 73.06% and RoNW 73.06%. The Annualised EPS based on the latest financial data is ₹ 8.36 and PE ratio is 13.27x. These metrics suggest that the IPO is fully priced.
The Grey Market Premium (GMP) of Amwill Healthcare showing potential listing gains of 0%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to Avoid to the Amwill Healthcare Limited IPO for Listing gain.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information.
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms during the training period. He is good at Technical analysis and Fundamental Analysis and uses both Technical and Fundamental analysis along with five other important factors that affect the movement of the Market namely Global Market Analysis, Upcoming Event Analysis, Institutional Money Analysis, Derivative Data Analysis, and Emotions and Sentiment of Traders and Investors in his Framework called - Technical Fundamental GUIDE to find the winning Trades.
Option Trading with CA Abhay
Equity Trading with CA Abhay
Stock Market Masterclass
FNO Stocks with CA Abhay
Equity Investment with CA Abhay
FNO Stocks with CA Abhay
Equity Investment with CA Abhay
Stock Market Masterclass
Option Trading with CA Abhay
Equity Trading with CA Abhay
Copyright @2020 Design & Developed by Info Web Software